| 1 | clinical | 181,724 |
| 2 | nederlands | 64 |
| 3 | 'clinical | 40 |
| 4 | primary-prevention | 13 |
| 5 | electroclinical | 11 |
| 6 | magpie | 10 |
| 7 | outcome-driven | 10 |
| 8 | clincal | 9 |
| 9 | randomized-clinical | 9 |
| 10 | amaros | 8 |
| 11 | community-intervention | 8 |
| 12 | titax-ami | 8 |
| 13 | cochrane-controlled | 7 |
| 14 | react-2 | 7 |
| 15 | trial-derived | 7 |
| 16 | claricor | 6 |
| 17 | dinical | 6 |
| 18 | oasis-6 | 6 |
| 19 | typical-use | 6 |
| 20 | eurythmics | 5 |
| 21 | methotrexate-experienced | 5 |
| 22 | professional-cluster | 5 |
| 23 | clincial | 4 |
| 24 | clinical/economic | 4 |
| 25 | treatment.two | 4 |
| 26 | velour | 4 |
| 27 | b32 | 3 |
| 28 | biology-driven | 3 |
| 29 | clinico-biological | 3 |
| 30 | elderly-specific | 3 |
| 31 | gissi-2/international | 3 |
| 32 | immunointervention | 3 |
| 33 | mavis | 3 |
| 34 | noncompleted | 3 |
| 35 | nonmortality | 3 |
| 36 | post-field | 3 |
| 37 | study-wise | 3 |
| 38 | symptom-reduction | 3 |
| 39 | -9802 | 2 |
| 40 | bias.most | 2 |
| 41 | bicombo | 2 |
| 42 | cbf-2006 | 2 |
| 43 | clini-cal | 2 |
| 44 | clinial | 2 |
| 45 | cognitive-domain | 2 |
| 46 | conko-004 | 2 |
| 47 | cycling-to-school | 2 |
| 48 | entreppment | 2 |
| 49 | eortc-30994 | 2 |
| 50 | events.later | 2 |
| 51 | events.two | 2 |
| 52 | fixed-sample-size | 2 |
| 53 | gast-05 | 2 |
| 54 | infection.further | 2 |
| 55 | inpulsis™ | 2 |
| 56 | low-craving | 2 |
| 57 | meta-analysis.four | 2 |
| 58 | miles-3 | 2 |
| 59 | multiple-membership | 2 |
| 60 | neoscope | 2 |
| 61 | neuroclinical | 2 |
| 62 | neuroemergency | 2 |
| 63 | nutrition-intervention | 2 |
| 64 | ongoing/completed | 2 |
| 65 | phase-clinical | 2 |
| 66 | platinum-wh | 2 |
| 67 | prevec | 2 |
| 68 | probe/open-label | 2 |
| 69 | quality.four | 2 |
| 70 | remedee | 2 |
| 71 | single-instillation | 2 |
| 72 | start-pilot | 2 |
| 73 | trials.thirteen | 2 |
| 74 | vaccination/challenge | 2 |
| 75 | vermont-oxford | 2 |
| 76 | 'research-enhanced | 1 |
| 77 | 'zero-event | 1 |
| 78 | /ii | 1 |
| 79 | 26week | 1 |
| 80 | 3-7-month | 1 |
| 81 | 37/68 | 1 |
| 82 | 4432 | 1 |
| 83 | 82,867 | 1 |
| 84 | activation.two | 1 |
| 85 | acute-diarrhea | 1 |
| 86 | adaptations.three | 1 |
| 87 | adults.one | 1 |
| 88 | agonist-alone | 1 |
| 89 | am-01 | 1 |
| 90 | artemis-hp | 1 |
| 91 | arthrodesis.six | 1 |
| 92 | avaluz | 1 |
| 93 | bbii | 1 |
| 94 | bbsa | 1 |
| 95 | bmd.no | 1 |
| 96 | bolero-3 | 1 |
| 97 | build-3 | 1 |
| 98 | cdc-tb | 1 |
| 99 | cedim-2 | 1 |
| 100 | chondrosarcomas.this | 1 |
| 101 | clinicat | 1 |
| 102 | cochranecontrolled | 1 |
| 103 | comparative-superiority | 1 |
| 104 | comparison.four | 1 |
| 105 | comparisons.no | 1 |
| 106 | compression.two | 1 |
| 107 | conclusion/clinical | 1 |
| 108 | conclusions.thirty-four | 1 |
| 109 | ctong1002 | 1 |
| 110 | deformity.three | 1 |
| 111 | depression-intervention | 1 |
| 112 | development-recent | 1 |
| 113 | disease.one | 1 |
| 114 | drugsthree | 1 |
| 115 | educa-ii | 1 |
| 116 | effects.eight | 1 |
| 117 | effects.nine | 1 |
| 118 | effects.twenty | 1 |
| 119 | enoxaparin-sufh | 1 |
| 120 | ethnophamacological | 1 |
| 121 | ethnopharmocological | 1 |
| 122 | ethnpharmacological | 1 |
| 123 | ethonopharmacological | 1 |
| 124 | events.fourteen | 1 |
| 125 | events.most | 1 |
| 126 | events.one | 1 |
| 127 | events.six | 1 |
| 128 | eventssixteen | 1 |
| 129 | five-randomised | 1 |
| 130 | full-match | 1 |
| 131 | functioning.four | 1 |
| 132 | functioning.six | 1 |
| 133 | functioning.two | 1 |
| 134 | gastritis-related | 1 |
| 135 | germany.clinical | 1 |
| 136 | gestation.three | 1 |
| 137 | getcb | 1 |
| 138 | graall-2003 | 1 |
| 139 | haemato | 1 |
| 140 | hd98b | 1 |
| 141 | here.ten | 1 |
| 142 | hi-light | 1 |
| 143 | high-craving | 1 |
| 144 | home.most | 1 |
| 145 | humans.this | 1 |
| 146 | ibscg | 1 |
| 147 | ibuprofen.six | 1 |
| 148 | intensity-activity | 1 |
| 149 | inter-des | 1 |
| 150 | interventions.eight | 1 |
| 151 | j-chf | 1 |
| 152 | j-wind | 1 |
| 153 | large-scale/long-term | 1 |
| 154 | licc | 1 |
| 155 | lowering-it | 1 |
| 156 | manner.numerous | 1 |
| 157 | manuscripts.seven | 1 |
| 158 | metronidazole-controlled | 1 |
| 159 | mm-003 | 1 |
| 160 | multi-location | 1 |
| 161 | multisite-randomized | 1 |
| 162 | nafld.this | 1 |
| 163 | narratively.two | 1 |
| 164 | nct01070394clinical | 1 |
| 165 | nct01154179 | 1 |
| 166 | nnt-associated | 1 |
| 167 | nofalls | 1 |
| 168 | norway.two | 1 |
| 169 | npc-9902 | 1 |
| 170 | nsabp-b27 | 1 |
| 171 | outcomes.seven | 1 |
| 172 | outcomes.twenty-two | 1 |
| 173 | paragon-hf | 1 |
| 174 | parent-blind | 1 |
| 175 | parents.two | 1 |
| 176 | patients.four | 1 |
| 177 | persistent-diarrhea | 1 |
| 178 | pfd-related | 1 |
| 179 | pharmacokinetic/safety | 1 |
| 180 | phase-ii-clinical | 1 |
| 181 | phase-ill | 1 |
| 182 | placebo.one | 1 |
| 183 | placebocontrol | 1 |
| 184 | practice-defining | 1 |
| 185 | procomb | 1 |
| 186 | prognosis.this | 1 |
| 187 | psychosocial/psychopharmacological | 1 |
| 188 | rct-style | 1 |
| 189 | relapse-controlled | 1 |
| 190 | repeat-following-correct | 1 |
| 191 | revascularization-2 | 1 |
| 192 | ropinirole-controlled | 1 |
| 193 | s9321 | 1 |
| 194 | sacura | 1 |
| 195 | sbv-controlled | 1 |
| 196 | secritt | 1 |
| 197 | spondylarthopathy | 1 |
| 198 | stent-versus-stent | 1 |
| 199 | stress/benestent | 1 |
| 200 | surgeon-randomized | 1 |
| 201 | tachyardia | 1 |
| 202 | tbi-clinical | 1 |
| 203 | tdr/undp | 1 |
| 204 | test-learning | 1 |
| 205 | theone | 1 |
| 206 | tiervlei | 1 |
| 207 | tolerance.seven | 1 |
| 208 | tranquillisation-clinical | 1 |
| 209 | trends.two | 1 |
| 210 | trials-rembrandt | 1 |
| 211 | trials.primary | 1 |
| 212 | trials/national | 1 |
| 213 | tsc.the | 1 |
| 214 | ultra-2 | 1 |
| 215 | us-nih | 1 |
| 216 | use.three | 1 |
| 217 | way.one | 1 |
| 218 | women.two | 1 |
| 1 | 'clinical | 40 |
| 2 | 'research-enhanced | 1 |
| 3 | 'zero-event | 1 |
| 4 | -9802 | 2 |
| 5 | /ii | 1 |
| 6 | 26week | 1 |
| 7 | 3-7-month | 1 |
| 8 | 37/68 | 1 |
| 9 | 4432 | 1 |
| 10 | 82,867 | 1 |
| 11 | activation.two | 1 |
| 12 | acute-diarrhea | 1 |
| 13 | adaptations.three | 1 |
| 14 | adults.one | 1 |
| 15 | agonist-alone | 1 |
| 16 | am-01 | 1 |
| 17 | amaros | 8 |
| 18 | artemis-hp | 1 |
| 19 | arthrodesis.six | 1 |
| 20 | avaluz | 1 |
| 21 | b32 | 3 |
| 22 | bbii | 1 |
| 23 | bbsa | 1 |
| 24 | bias.most | 2 |
| 25 | bicombo | 2 |
| 26 | biology-driven | 3 |
| 27 | bmd.no | 1 |
| 28 | bolero-3 | 1 |
| 29 | build-3 | 1 |
| 30 | cbf-2006 | 2 |
| 31 | cdc-tb | 1 |
| 32 | cedim-2 | 1 |
| 33 | chondrosarcomas.this | 1 |
| 34 | claricor | 6 |
| 35 | clincal | 9 |
| 36 | clincial | 4 |
| 37 | clini-cal | 2 |
| 38 | clinial | 2 |
| 39 | clinical | 181,724 |
| 40 | clinical/economic | 4 |
| 41 | clinicat | 1 |
| 42 | clinico-biological | 3 |
| 43 | cochrane-controlled | 7 |
| 44 | cochranecontrolled | 1 |
| 45 | cognitive-domain | 2 |
| 46 | community-intervention | 8 |
| 47 | comparative-superiority | 1 |
| 48 | comparison.four | 1 |
| 49 | comparisons.no | 1 |
| 50 | compression.two | 1 |
| 51 | conclusion/clinical | 1 |
| 52 | conclusions.thirty-four | 1 |
| 53 | conko-004 | 2 |
| 54 | ctong1002 | 1 |
| 55 | cycling-to-school | 2 |
| 56 | deformity.three | 1 |
| 57 | depression-intervention | 1 |
| 58 | development-recent | 1 |
| 59 | dinical | 6 |
| 60 | disease.one | 1 |
| 61 | drugsthree | 1 |
| 62 | educa-ii | 1 |
| 63 | effects.eight | 1 |
| 64 | effects.nine | 1 |
| 65 | effects.twenty | 1 |
| 66 | elderly-specific | 3 |
| 67 | electroclinical | 11 |
| 68 | enoxaparin-sufh | 1 |
| 69 | entreppment | 2 |
| 70 | eortc-30994 | 2 |
| 71 | ethnophamacological | 1 |
| 72 | ethnopharmocological | 1 |
| 73 | ethnpharmacological | 1 |
| 74 | ethonopharmacological | 1 |
| 75 | eurythmics | 5 |
| 76 | events.fourteen | 1 |
| 77 | events.later | 2 |
| 78 | events.most | 1 |
| 79 | events.one | 1 |
| 80 | events.six | 1 |
| 81 | events.two | 2 |
| 82 | eventssixteen | 1 |
| 83 | five-randomised | 1 |
| 84 | fixed-sample-size | 2 |
| 85 | full-match | 1 |
| 86 | functioning.four | 1 |
| 87 | functioning.six | 1 |
| 88 | functioning.two | 1 |
| 89 | gast-05 | 2 |
| 90 | gastritis-related | 1 |
| 91 | germany.clinical | 1 |
| 92 | gestation.three | 1 |
| 93 | getcb | 1 |
| 94 | gissi-2/international | 3 |
| 95 | graall-2003 | 1 |
| 96 | haemato | 1 |
| 97 | hd98b | 1 |
| 98 | here.ten | 1 |
| 99 | hi-light | 1 |
| 100 | high-craving | 1 |
| 101 | home.most | 1 |
| 102 | humans.this | 1 |
| 103 | ibscg | 1 |
| 104 | ibuprofen.six | 1 |
| 105 | immunointervention | 3 |
| 106 | infection.further | 2 |
| 107 | inpulsis™ | 2 |
| 108 | intensity-activity | 1 |
| 109 | inter-des | 1 |
| 110 | interventions.eight | 1 |
| 111 | j-chf | 1 |
| 112 | j-wind | 1 |
| 113 | large-scale/long-term | 1 |
| 114 | licc | 1 |
| 115 | low-craving | 2 |
| 116 | lowering-it | 1 |
| 117 | magpie | 10 |
| 118 | manner.numerous | 1 |
| 119 | manuscripts.seven | 1 |
| 120 | mavis | 3 |
| 121 | meta-analysis.four | 2 |
| 122 | methotrexate-experienced | 5 |
| 123 | metronidazole-controlled | 1 |
| 124 | miles-3 | 2 |
| 125 | mm-003 | 1 |
| 126 | multi-location | 1 |
| 127 | multiple-membership | 2 |
| 128 | multisite-randomized | 1 |
| 129 | nafld.this | 1 |
| 130 | narratively.two | 1 |
| 131 | nct01070394clinical | 1 |
| 132 | nct01154179 | 1 |
| 133 | nederlands | 64 |
| 134 | neoscope | 2 |
| 135 | neuroclinical | 2 |
| 136 | neuroemergency | 2 |
| 137 | nnt-associated | 1 |
| 138 | nofalls | 1 |
| 139 | noncompleted | 3 |
| 140 | nonmortality | 3 |
| 141 | norway.two | 1 |
| 142 | npc-9902 | 1 |
| 143 | nsabp-b27 | 1 |
| 144 | nutrition-intervention | 2 |
| 145 | oasis-6 | 6 |
| 146 | ongoing/completed | 2 |
| 147 | outcome-driven | 10 |
| 148 | outcomes.seven | 1 |
| 149 | outcomes.twenty-two | 1 |
| 150 | paragon-hf | 1 |
| 151 | parent-blind | 1 |
| 152 | parents.two | 1 |
| 153 | patients.four | 1 |
| 154 | persistent-diarrhea | 1 |
| 155 | pfd-related | 1 |
| 156 | pharmacokinetic/safety | 1 |
| 157 | phase-clinical | 2 |
| 158 | phase-ii-clinical | 1 |
| 159 | phase-ill | 1 |
| 160 | placebo.one | 1 |
| 161 | placebocontrol | 1 |
| 162 | platinum-wh | 2 |
| 163 | post-field | 3 |
| 164 | practice-defining | 1 |
| 165 | prevec | 2 |
| 166 | primary-prevention | 13 |
| 167 | probe/open-label | 2 |
| 168 | procomb | 1 |
| 169 | professional-cluster | 5 |
| 170 | prognosis.this | 1 |
| 171 | psychosocial/psychopharmacological | 1 |
| 172 | quality.four | 2 |
| 173 | randomized-clinical | 9 |
| 174 | rct-style | 1 |
| 175 | react-2 | 7 |
| 176 | relapse-controlled | 1 |
| 177 | remedee | 2 |
| 178 | repeat-following-correct | 1 |
| 179 | revascularization-2 | 1 |
| 180 | ropinirole-controlled | 1 |
| 181 | s9321 | 1 |
| 182 | sacura | 1 |
| 183 | sbv-controlled | 1 |
| 184 | secritt | 1 |
| 185 | single-instillation | 2 |
| 186 | spondylarthopathy | 1 |
| 187 | start-pilot | 2 |
| 188 | stent-versus-stent | 1 |
| 189 | stress/benestent | 1 |
| 190 | study-wise | 3 |
| 191 | surgeon-randomized | 1 |
| 192 | symptom-reduction | 3 |
| 193 | tachyardia | 1 |
| 194 | tbi-clinical | 1 |
| 195 | tdr/undp | 1 |
| 196 | test-learning | 1 |
| 197 | theone | 1 |
| 198 | tiervlei | 1 |
| 199 | titax-ami | 8 |
| 200 | tolerance.seven | 1 |
| 201 | tranquillisation-clinical | 1 |
| 202 | treatment.two | 4 |
| 203 | trends.two | 1 |
| 204 | trial-derived | 7 |
| 205 | trials-rembrandt | 1 |
| 206 | trials.primary | 1 |
| 207 | trials.thirteen | 2 |
| 208 | trials/national | 1 |
| 209 | tsc.the | 1 |
| 210 | typical-use | 6 |
| 211 | ultra-2 | 1 |
| 212 | us-nih | 1 |
| 213 | use.three | 1 |
| 214 | vaccination/challenge | 2 |
| 215 | velour | 4 |
| 216 | vermont-oxford | 2 |
| 217 | way.one | 1 |
| 218 | women.two | 1 |
| 1 | am-01 | 1 |
| 2 | s9321 | 1 |
| 3 | ultra-2 | 1 |
| 4 | cedim-2 | 1 |
| 5 | revascularization-2 | 1 |
| 6 | react-2 | 7 |
| 7 | ctong1002 | 1 |
| 8 | -9802 | 2 |
| 9 | npc-9902 | 1 |
| 10 | 4432 | 1 |
| 11 | b32 | 3 |
| 12 | build-3 | 1 |
| 13 | bolero-3 | 1 |
| 14 | miles-3 | 2 |
| 15 | mm-003 | 1 |
| 16 | graall-2003 | 1 |
| 17 | conko-004 | 2 |
| 18 | eortc-30994 | 2 |
| 19 | gast-05 | 2 |
| 20 | oasis-6 | 6 |
| 21 | cbf-2006 | 2 |
| 22 | nsabp-b27 | 1 |
| 23 | 82,867 | 1 |
| 24 | 37/68 | 1 |
| 25 | nct01154179 | 1 |
| 26 | acute-diarrhea | 1 |
| 27 | persistent-diarrhea | 1 |
| 28 | tachyardia | 1 |
| 29 | sacura | 1 |
| 30 | bbsa | 1 |
| 31 | hd98b | 1 |
| 32 | getcb | 1 |
| 33 | procomb | 1 |
| 34 | cdc-tb | 1 |
| 35 | licc | 1 |
| 36 | prevec | 2 |
| 37 | elderly-specific | 3 |
| 38 | clinical/economic | 4 |
| 39 | 'research-enhanced | 1 |
| 40 | methotrexate-experienced | 5 |
| 41 | ropinirole-controlled | 1 |
| 42 | metronidazole-controlled | 1 |
| 43 | cochrane-controlled | 7 |
| 44 | relapse-controlled | 1 |
| 45 | sbv-controlled | 1 |
| 46 | cochranecontrolled | 1 |
| 47 | five-randomised | 1 |
| 48 | nnt-associated | 1 |
| 49 | pfd-related | 1 |
| 50 | gastritis-related | 1 |
| 51 | ongoing/completed | 2 |
| 52 | noncompleted | 3 |
| 53 | trial-derived | 7 |
| 54 | multisite-randomized | 1 |
| 55 | surgeon-randomized | 1 |
| 56 | post-field | 3 |
| 57 | parent-blind | 1 |
| 58 | j-wind | 1 |
| 59 | vermont-oxford | 2 |
| 60 | remedee | 2 |
| 61 | use.three | 1 |
| 62 | gestation.three | 1 |
| 63 | adaptations.three | 1 |
| 64 | deformity.three | 1 |
| 65 | drugsthree | 1 |
| 66 | vaccination/challenge | 2 |
| 67 | tsc.the | 1 |
| 68 | magpie | 10 |
| 69 | rct-style | 1 |
| 70 | effects.nine | 1 |
| 71 | disease.one | 1 |
| 72 | placebo.one | 1 |
| 73 | adults.one | 1 |
| 74 | events.one | 1 |
| 75 | way.one | 1 |
| 76 | theone | 1 |
| 77 | agonist-alone | 1 |
| 78 | neoscope | 2 |
| 79 | study-wise | 3 |
| 80 | typical-use | 6 |
| 81 | fixed-sample-size | 2 |
| 82 | paragon-hf | 1 |
| 83 | j-chf | 1 |
| 84 | ibscg | 1 |
| 85 | practice-defining | 1 |
| 86 | test-learning | 1 |
| 87 | high-craving | 1 |
| 88 | low-craving | 2 |
| 89 | full-match | 1 |
| 90 | enoxaparin-sufh | 1 |
| 91 | us-nih | 1 |
| 92 | 3-7-month | 1 |
| 93 | platinum-wh | 2 |
| 94 | tiervlei | 1 |
| 95 | educa-ii | 1 |
| 96 | /ii | 1 |
| 97 | bbii | 1 |
| 98 | titax-ami | 8 |
| 99 | 26week | 1 |
| 100 | clini-cal | 2 |
| 101 | ethnophamacological | 1 |
| 102 | ethnpharmacological | 1 |
| 103 | psychosocial/psychopharmacological | 1 |
| 104 | ethonopharmacological | 1 |
| 105 | ethnopharmocological | 1 |
| 106 | clinico-biological | 3 |
| 107 | dinical | 6 |
| 108 | clinical | 181,724 |
| 109 | 'clinical | 40 |
| 110 | randomized-clinical | 9 |
| 111 | phase-clinical | 2 |
| 112 | tbi-clinical | 1 |
| 113 | phase-ii-clinical | 1 |
| 114 | tranquillisation-clinical | 1 |
| 115 | germany.clinical | 1 |
| 116 | conclusion/clinical | 1 |
| 117 | nct01070394clinical | 1 |
| 118 | electroclinical | 11 |
| 119 | neuroclinical | 2 |
| 120 | clincal | 9 |
| 121 | clincial | 4 |
| 122 | clinial | 2 |
| 123 | trials/national | 1 |
| 124 | gissi-2/international | 3 |
| 125 | probe/open-label | 2 |
| 126 | phase-ill | 1 |
| 127 | cycling-to-school | 2 |
| 128 | placebocontrol | 1 |
| 129 | large-scale/long-term | 1 |
| 130 | trials.thirteen | 2 |
| 131 | events.fourteen | 1 |
| 132 | eventssixteen | 1 |
| 133 | here.ten | 1 |
| 134 | tolerance.seven | 1 |
| 135 | outcomes.seven | 1 |
| 136 | manuscripts.seven | 1 |
| 137 | outcome-driven | 10 |
| 138 | biology-driven | 3 |
| 139 | cognitive-domain | 2 |
| 140 | multi-location | 1 |
| 141 | single-instillation | 2 |
| 142 | symptom-reduction | 3 |
| 143 | primary-prevention | 13 |
| 144 | depression-intervention | 1 |
| 145 | nutrition-intervention | 2 |
| 146 | community-intervention | 8 |
| 147 | immunointervention | 3 |
| 148 | bicombo | 2 |
| 149 | bmd.no | 1 |
| 150 | comparisons.no | 1 |
| 151 | haemato | 1 |
| 152 | outcomes.twenty-two | 1 |
| 153 | functioning.two | 1 |
| 154 | women.two | 1 |
| 155 | compression.two | 1 |
| 156 | activation.two | 1 |
| 157 | trends.two | 1 |
| 158 | parents.two | 1 |
| 159 | events.two | 2 |
| 160 | treatment.two | 4 |
| 161 | norway.two | 1 |
| 162 | narratively.two | 1 |
| 163 | tdr/undp | 1 |
| 164 | artemis-hp | 1 |
| 165 | multiple-membership | 2 |
| 166 | infection.further | 2 |
| 167 | events.later | 2 |
| 168 | professional-cluster | 5 |
| 169 | claricor | 6 |
| 170 | conclusions.thirty-four | 1 |
| 171 | functioning.four | 1 |
| 172 | comparison.four | 1 |
| 173 | meta-analysis.four | 2 |
| 174 | patients.four | 1 |
| 175 | quality.four | 2 |
| 176 | velour | 4 |
| 177 | eurythmics | 5 |
| 178 | nederlands | 64 |
| 179 | inter-des | 1 |
| 180 | nafld.this | 1 |
| 181 | chondrosarcomas.this | 1 |
| 182 | prognosis.this | 1 |
| 183 | humans.this | 1 |
| 184 | mavis | 3 |
| 185 | nofalls | 1 |
| 186 | amaros | 8 |
| 187 | manner.numerous | 1 |
| 188 | clinicat | 1 |
| 189 | repeat-following-correct | 1 |
| 190 | trials-rembrandt | 1 |
| 191 | interventions.eight | 1 |
| 192 | effects.eight | 1 |
| 193 | hi-light | 1 |
| 194 | lowering-it | 1 |
| 195 | development-recent | 1 |
| 196 | entreppment | 2 |
| 197 | stent-versus-stent | 1 |
| 198 | stress/benestent | 1 |
| 199 | 'zero-event | 1 |
| 200 | start-pilot | 2 |
| 201 | home.most | 1 |
| 202 | bias.most | 2 |
| 203 | events.most | 1 |
| 204 | secritt | 1 |
| 205 | functioning.six | 1 |
| 206 | ibuprofen.six | 1 |
| 207 | arthrodesis.six | 1 |
| 208 | events.six | 1 |
| 209 | neuroemergency | 2 |
| 210 | spondylarthopathy | 1 |
| 211 | trials.primary | 1 |
| 212 | pharmacokinetic/safety | 1 |
| 213 | nonmortality | 3 |
| 214 | comparative-superiority | 1 |
| 215 | intensity-activity | 1 |
| 216 | effects.twenty | 1 |
| 217 | avaluz | 1 |
| 218 | inpulsis™ | 2 |